{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:17:29Z","timestamp":1780507049837,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Zoledronic acid (ZOL) is an intravenous bisphosphonate indicated for the use of hypercalcemia of malignancy and management of bony metastases. Its therapeutic effect lies in the targeting of malignant osteoclasts; however, administration can be associated with renal toxicity. The objective of this retrospective study was to evaluate the frequency and severity of acute kidney injury (AKI) following ZOL administration in a cohort of cancer-bearing dogs. A pharmacy search was conducted to identify dogs that received a dose of ZOL between June 2016 and July 2019. Inclusion criteria included baseline and post-treatment chemistry panels. Medical records were reviewed to obtain clinical data including signalment, dose, dosage, number of treatments administered, and changes in renal function. Forty-four dogs met the inclusion criteria. Median number of doses administered was three [interquartile range (IQR), 2\u20135]. The median highest creatinine value occurred after a median of one dose (IQR, 1\u20132 doses) compared with the median highest value of blood urea nitrogen, phosphorus, and potassium, which occurred after a median of two doses (IQR, 1\u20133). Six (13.6%) dogs developed an AKI, and one dog (2.3%) had progression of an existing azotemia after treatment with ZOL was initiated. Two dogs (4.5%) had ZOL treatment discontinued secondary to development of azotemia. Use of concurrent administration of non-steroidal anti-inflammatory drugs or anesthesia did not significantly increase the risk of AKI in this cohort of dogs. Acute kidney injury is observed infrequently in cancer-bearing dogs treated with ZOL and is generally mild to moderate in severity; discontinuation of ZOL due to AKI is uncommon.<\/jats:p>","DOI":"10.3389\/fvets.2021.647846","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T04:27:33Z","timestamp":1625200053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid Administration to Dogs With Malignant Osteolysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Sarah A.","family":"Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Skorupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Willcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna H.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.cvsm.2007.08.002","article-title":"The role of bisphosphonates in the management of patients that have cancer","volume":"37","author":"Fan","year":"2007","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic acid and renal toxicity: data from french adverse effect reporting database","volume":"39","author":"Munier","year":"2005","journal-title":"Ann Pharmacother."},{"key":"B3","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin Cancer Res."},{"key":"B4","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","article-title":"Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone","volume":"1","author":"Saad","year":"2002","journal-title":"Clin Prostate Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.amjmed.2018.04.028","article-title":"Paget's disease of bone: diagnosis and treatment","volume":"131","author":"Kravets","year":"2018","journal-title":"Am J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1939-1676.2008.0221.x","article-title":"Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain","volume":"23","author":"Fan","year":"2009","journal-title":"J Vet Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1939-1676.2005.tb02661.x","article-title":"Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement","volume":"19","author":"Fan","year":"2005","journal-title":"J Vet Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1939-1676.2007.tb02986.x","article-title":"Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain","volume":"21","author":"Fan","year":"2007","journal-title":"J Vet Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/vco.12040","article-title":"Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma","volume":"13","author":"Kozicki","year":"2015","journal-title":"Vet Comp Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1532-950X.2012.00968.x","article-title":"The impact of pamidronate and chemotherapy on survival times in dogs with appendicular primary bone tumors treated with palliative radiation therapy","volume":"41","author":"Oblak","year":"2012","journal-title":"Vet Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1939-1676.2004.tb02593.x","article-title":"Bisphosphonates and cancer","volume":"18","author":"Milner","year":"2004","journal-title":"J Vet Intern Med."},{"key":"B15","unstructured":"2014"},{"key":"B16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1939-1676.2008.0046.x","article-title":"The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis","volume":"22","author":"Fan","year":"2008","journal-title":"J Vet Intern Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e54604","DOI":"10.5326\/JAAHA-MS-6681","article-title":"Evaluation of zoledronate as treatment for hypercalcemia in four dogs","volume":"54","author":"Schenk","year":"2018","journal-title":"J Am Anim Hosp Assoc."},{"key":"B18","unstructured":"2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"10","author":"Body","year":"2005","journal-title":"Oncologist."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","volume":"14","year":"2016","journal-title":"Vet Comp Oncol."},{"key":"B22","unstructured":"Grading of Acute Kidney Injury2016"},{"key":"B23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/sdi.12388","article-title":"Pharmacology of bisphosphonates in patients with chronic kidney disease","volume":"28","author":"Ott","year":"2015","journal-title":"Semin Dial."},{"key":"B24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol Toxicol."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2021.647846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T04:27:36Z","timestamp":1625200056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2021.647846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":24,"alternative-id":["10.3389\/fvets.2021.647846"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2021.647846","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"article-number":"647846"}}